Warm Springs Advisors Inc. Cuts Holdings in Boston Scientific Corporation $BSX

by · The Cerbat Gem

Warm Springs Advisors Inc. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 13.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 6,635 shares of the medical equipment provider’s stock after selling 991 shares during the period. Warm Springs Advisors Inc.’s holdings in Boston Scientific were worth $713,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BSX. 1248 Management LLC purchased a new stake in Boston Scientific during the first quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific in the 1st quarter worth about $27,000. Sound Income Strategies LLC increased its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Princeton Global Asset Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at about $32,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific in the 2nd quarter worth approximately $37,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 175,782 shares of company stock valued at $17,742,314 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on BSX shares. The Goldman Sachs Group reiterated a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a research report on Wednesday, October 22nd. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Barclays increased their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price target for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $123.77.

View Our Latest Stock Analysis on BSX

Boston Scientific Trading Up 0.1%

NYSE BSX opened at $99.00 on Friday. The firm has a market capitalization of $146.69 billion, a PE ratio of 52.94, a P/E/G ratio of 2.02 and a beta of 0.58. The stock’s 50 day moving average is $100.20 and its 200 day moving average is $102.40. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).